LOW FEASIBILITY OF SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH DIABETES MELLITUS IN ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Kogure, Yoshihito [1 ]
Hori, Kazumi [1 ]
Funahashi, Yoriko [1 ]
Oka, Saori [1 ]
Tsuboi, Rie [1 ]
Adachi, Takashi [1 ]
Ryuge, Misaki [1 ]
Murata, Naohiko [1 ]
Kitagawa, Chiyoe [1 ]
Oki, Masahide [1 ]
Saka, Hideo [1 ]
机构：
[1] Nagoya Med Ctr, Nagoya, Aichi, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; Chemotherapy; diabetes mellitus;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1182 / S1183
页数：2
相关论文
共 50 条
  • [41] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [42] Second-line treatment options in advanced non-small cell lung cancer: Current status
    Cullen, M
    SEMINARS IN ONCOLOGY, 2006, 33 (01) : S3 - S8
  • [43] Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
    Reck, Martin
    Garassino, Marina Chiara
    Imbimbo, Martina
    Shepherd, Frances A.
    Socinski, Mark A.
    Shih, Jin-Yuan
    Tsao, Anne
    Lee, Pablo
    Winfree, Katherine B.
    Sashegyi, Andreas
    Cheng, Rebecca
    Varea, Rocio
    Levy, Benjamin
    Garon, Edward
    LUNG CANCER, 2018, 120 : 62 - 69
  • [44] Predictors and Impact of Second-line Chemotherapy Administration for Advanced Non-small Cell Lung Cancer (NSCLC): Implications for the Consideration of Maintenance Chemotherapy
    Gerber, D. E.
    Rasco, D. W.
    Le, P.
    Yan, J.
    Xie, Y.
    Dowell, J. E.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S534 - S534
  • [45] Second-line chemotherapy for non-small-cell lung cancer.
    Fossella F.V.
    Current Oncology Reports, 2000, 2 (1) : 96 - 101
  • [46] Second line chemotherapy with weekly paclitaxel in advanced non-small cell lung cancer.
    Leon, L
    Cueva, J
    Cudel, T
    Calvo, M
    Graña, B
    Padín, E
    Candamio, S
    Barón, F
    López, R
    ANNALS OF ONCOLOGY, 2000, 11 : 121 - 121
  • [47] Docetaxel as second-line chemotherapy for non-small-cell lung cancer
    Roila, F
    Del Favero, A
    Ballatori, E
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 3738 - 3738
  • [48] CHEMOTHERAPY VERSUS ERLOTINIB IN THE SECOND LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Fiala, Ondrej
    Pesek, Milos
    Krejci, Jana
    Sticha, Michal
    Minarik, Marek
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1259 - S1260
  • [49] Optimal duration of chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC) in the first- and second-line settings
    Grossi, F.
    Belvedere, O.
    Defferrari, C.
    Brianti, A.
    Follador, A.
    Rijavec, E.
    Ceschia, T.
    Pronzato, P.
    Fasola, G.
    Aita, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer
    Wong, Wenjing
    Sun, Ping
    Mu, Zhengbin
    Liu, Jiannan
    Yu, Caiyan
    Liu, Aina
    ANTICANCER RESEARCH, 2017, 37 (08) : 4687 - 4691
12345